Polarean Imaging : Interim Results for the six months ended 30 June 2021

2 September 2021

Polarean Imaging Plc

("Polarean" or the "Company")

Half-year Report

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with an investigational drug-device combination product for magnetic resonance imaging (MRI), announces its unaudited interim results for the six months ended 30 June 2021.

Highlights

• Raised £27 million gross proceeds in an oversubscribed financing, including continued support of strategic investors, Bracco Imaging S.p.A and Nukem Isotopes GmbH as well as institutional investor Amati AIM VCT plc, joined by several new UK and US institutional investors.
• Appointment of Chief Financial Officer, Chuck Osborne, to the Board
• Additional research unit order for a 9820 Xenon Polariser system from the University of British Columbia in Vancouver, Canada
• Installation of its 9820 Xenon Polariser system for the University of Texas MD Anderson Cancer Center
• Presentation of data at both the American Thoracic Society ("ATS") and the International Society for Magnetic Resonance in Medicine ("ISMRM") virtual conferences
• Publication of first peer reviewed COVID-19 research by Professor Fergus Gleeson at the University of Oxford
• Net cash of US$38.2m as of 30 June 2021

Post-period end

• Frequent interactions with the FDA as they review the NDA in advance of our target PDUFA goal date of 5 October 2021
• Preparation for launch of product including recruitment of employees into our sales and marketing organization
• Planning to broaden the awareness of Polarean technology through exhibitions at CHEST and RSNA 2021 and numerous topical conferences

Richard Hullihen, CEO of Polarean, commented: "During the first half of 2021 the Company raised its largest financing to date with its oversubscribed £27 million gross proceeds financing. We appreciate the continued support from our existing strategic, institutional and retail investors and welcome several new significant institutional investors. The proceeds from this round are being used to plan and execute the launch of our product in accordance with our current target PDUFA date of 5 October 2021. We continue to sell new polarisers systems for research use, as the amount of polarised Xenon research continues to increase. We look forward to providing our shareholders with updates regarding further progress and specifically the status of our target PDUFA date of 5 October 2021, and we thank them for their continued support on this exciting journey."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.

Enquiries:
Polarean Imaging plc	www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer	Via Walbrook PR
Jonathan Allis, Chairman

Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)

Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking) [phone] Nick Adams / Fred Walsh (Corporate Broking)

Walbrook PR	Tel: [phone] or [e-mail]
Paul McManus / Anna Dunphy	Mob: [phone]

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation. 129Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream.

In October 2020, the Group submitted a New Drug Application ("NDA") to the FDA for hyperpolarised 129Xe used to evaluate pulmonary function and to visualise the lung using MRI. In December 2020, the Group received confirmation of acceptance of its NDA by the FDA, with a target PDUFA action date of 5 October 2021.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

CEO Statement

Introduction

The six month period ending 30 June 2021 has seen Polarean make substantial progress towards its goal of seeking FDA approval for the Company's drug-device combination. As in the normal course, post submission, the Company has responded to the question and answer process with the FDA for our submission, while preparing itself and verifying the preparation of its suppliers and providers.

In January, the Company appointed a new Nominated Advisor and Broker, Stifel Nicolaus Europe Limited, which led to a successful placing, subscription, and open offer which was oversubscribed in every category, including its strategic investors Nukem Isotopes and Bracco. Then in February, Chuck Osborne, the existing CFO, was appointed to the Board in order to further leverage his extensive experience in early-stage life science company management, build out and fund raising.

During challenging times in healthcare and hospital utilization, we continued to take research orders from leading academic centres such as BC Children's hospital in Vancouver and also to build and deliver systems, completing the installation at MD Anderson Cancer Center in Houston.

Presentation at Medical Conferences and Studies Utilising our Technology

The Company's technology was once again prominent at the ATS and ISMRM virtual conference during May 2021 with over 50 abstracts related to the use of hyperpolarised 129Xe accepted for presentation at the two conferences. The content of our publications and those of our customers, along with our participation is available on our website at www.polarean.com. The user base of our polarisers continues to expand and document the applications of our technology across the spectrum of pulmonary disease.

Importantly, the first peer reviewed article on COVID-19 Long Haul patients visualised using 129Xe have now been published (https://pubs.rsna.org/doi/10.1148/radiol.2021210033). Additional investigator-initiatedgovernment research grants are underway to study the use of our technology to assess the long-termeffects of COVID-19infection in patients.

Results overview

Group revenues for the first half were US$0.6m (2020: US$0.3m) and were largely derived from the sale of a polariser system to MD Anderson, in contrast to the H1 2020 revenue, which was largely from our collaboration with the University of Cincinnati for work under our SBIR grant, which has now been completed. We continue to sell our polariser systems on a research-use-only basis to academic institutions in the US, Canada and Europe. Operating expenses for H1 2021 (US$5.5m) increased from H1 2020 (US$3.4m), as Selling and Distribution Expenses (H1 2021 US$1.8m, H1 2020 US $0.4m) increased as we are executing our plans for commercial launch. During H1 2021, the Company recognized Finance Income of US$0.4m due to the strengthening of the British pound, which more than offset the US$0.3m forgivable loan under the US Paycheck Protection Program ("PPP") we received and recognized as Finance Income in H1 2020. Our overall loss before tax increased from US$3.2m to US$4.9m in the same comparable period, due primarily to the commercial launch preparation expenses. The Company completed a £27m (~$37m) fundraise during H1 2021 via the issue of new equity and as at 30 June 2021 we held US US$38.2m in net cash or cash equivalents.

Post-period end events

FDA review of NDA

We continue to interact with the FDA as they review our NDA with a target date PDUFA date of 5 October 2021.

Preparation for launch

We continue to prepare for the potential launch of our drug device combination post FDA approval. In particular, we have been building a sales and marketing organization with the recent recruitment of several sales positions.

Planning for conference exhibitions

We are continuing to increase the awareness of Polarean technology with exhibitions at CHEST in October 2021 and RSNA in December 2021.

Research polarisers

Researchers continue to apply for and receive grants to purchase our polariser systems, most recently BC Children's Hospital in Vancouver, BC. This system has been delivered and is proceeding to installation. We are in discussions with several research institutions and anticipate additional possible orders during calendar year 2021.

Outlook

We continue to demonstrate that Polarean's technology has the potential to be of tremendous benefit to patients and a powerful new tool for clinicians in discovering and characterising treatable traits in pulmonary medicine. In addition, our latest new techniques lead us into the field of cardiology and pulmonary vascular disease which is one example of the further potential of our technology. We also look forward to evaluating new uses of our technology in pharmaceutical drug development.

The burden of pulmonary disease in the USA is approximately US$150bn and is widespread and growing, affecting nearly 40 million Americans and 500 million worldwide, with post COVID patients comprising a new segment approaching the scale of asthma. Given the limitations of existing methods of diagnosis and lung disease monitoring, we estimate that there is a significant unmet need for safe, non-invasive, quantitative, and cost-effective image- based diagnosis technology. We believe that our unique medical drug-device combination utilising 129Xe offers the ideal solution for improving pulmonary disease diagnosis.

This is an exciting time for the Company, as we enter the final stages of submitting our NDA and look towards a potential commercial launch before the end of 2021.

Richard Hullihen

Chief Executive Officer

2 September 2021

POLAREAN IMAGING PLC

Consolidated unaudited statement of comprehensive income for the six months ended 30 June 2021

		Unaudited		Unaudited		Audited
		6 months		6 months		12 months
		ended		ended		ended
		30.6.21	30.6.20	31.12.20
		US$		US$		US$
	Note
Revenue		621,874	327,896	1,056,766
Cost of sales		(323,185)		(41,387)		(346,300)
Gross profit		298,689	286,509	710,466
Administrative expenses		(2,915,214)	(2,724,411)	(5,049,246)
Depreciation		(81,320)	(73,204)	(150,224)
Amortisation		(375,861)	(359,677)	(734,058)
Selling and distribution expenses		(1,799,324)	(351,754)	(917,783)
Share based payment expense		(367,397)	(213,906)	(474,716)
Loss from operations		(5,240,427)	(3,436,443)	(6,615,562)
Finance expense		(8,261)	(9,647)	(19,730)
Finance income		393,392	267,155	100,769
Loss on ordinary activities before taxation	3	(4,855,296)	(3,178,935)	(6,534,523)
Taxation		-	-	-
Loss and total other comprehensive expense		(4,855,296)	(3,178,935)	(6,534,523)
Basic and fully diluted loss per share (US$)	3	(0.026)	(0.023)	(0.044)